149 related articles for article (PubMed ID: 6109013)
1. Pimozide: delayed onset of action at rat striatal pre- and postsynaptic dopamine receptors.
McMillen BA; German DC; Sanghere MK; Warnack W; Shore PA
J Pharmacol Exp Ther; 1980 Oct; 215(1):150-5. PubMed ID: 6109013
[TBL] [Abstract][Full Text] [Related]
2. Effects of buspirone on dopamine dependent behaviours in rats.
Dhavalshankh AG; Jadhav SA; Gaikwad RV; Gaonkar RK; Thorat VM; Balsara JJ
Indian J Physiol Pharmacol; 2007; 51(4):375-86. PubMed ID: 18476392
[TBL] [Abstract][Full Text] [Related]
3. Evidence for multiple dopamine receptors involved in the modulation of acetylcholine release in the striatum.
Hársing LG; Vizi ES
Pol J Pharmacol Pharm; 1985; 37(3):383-96. PubMed ID: 2866504
[TBL] [Abstract][Full Text] [Related]
4. Effects of BMY 14802, a potential antipsychotic drug, on rat brain dopaminergic function.
Matthews RT; McMillen BA; Sallis R; Blair D
J Pharmacol Exp Ther; 1986 Oct; 239(1):124-31. PubMed ID: 2876091
[TBL] [Abstract][Full Text] [Related]
5. Effects of dextromethorphan on dopamine dependent behaviours in rats.
Gaikwad RV; Gaonkar RK; Jadhav SA; Thorat VM; Jadhav JH; Balsara JJ
Indian J Exp Biol; 2007 Aug; 45(8):712-9. PubMed ID: 17877148
[TBL] [Abstract][Full Text] [Related]
6. Effect of supersensitivity of pre- and postsynaptic dopamine receptors on the activity of endogenous inhibitor of cAMP dependent protein kinase in rat striatum.
Szmigielski A; Szadowska A; Szmigielska H
Arch Int Pharmacodyn Ther; 1984 Dec; 272(2):214-24. PubMed ID: 6098230
[TBL] [Abstract][Full Text] [Related]
7. S 16924 ((R)-2-[1-[2-(2,3-dihydro-benzo[1,4] dioxin-5-Yloxy)-ethyl]-pyrrolidin-3yl]-1-(4-fluoro-phenyl)-ethanone), a novel, potential antipsychotic with marked serotonin (5-HT)1A agonist properties: I. Receptorial and neurochemical profile in comparison with clozapine and haloperidol.
Millan MJ; Gobert A; Newman-Tancredi A; Audinot V; Lejeune F; Rivet JM; Cussac D; Nicolas JP; Muller O; Lavielle G
J Pharmacol Exp Ther; 1998 Sep; 286(3):1341-55. PubMed ID: 9732398
[TBL] [Abstract][Full Text] [Related]
8. [Effect of repeated haloperidol and apomorphine administration on the development of tolerance for catalepsy and dopamine receptor hypersensitivity in mice].
Zharkovskiĭ AM; Matvienko OA; Nurk AM
Biull Eksp Biol Med; 1984 Oct; 98(10):444-6. PubMed ID: 6541951
[TBL] [Abstract][Full Text] [Related]
9. Potentiation of cataleptogenic effects of neuroleptics by prostaglandins.
Herman ZS; Słomińska-Zurek J; Kryk A; Kmieciak-Kołada K
Pol J Pharmacol Pharm; 1978; 30(5):639-46. PubMed ID: 35782
[TBL] [Abstract][Full Text] [Related]
10. Self-inhibitory dopamine-receptors and central effects of apomorphine.
Di Chiara G; Porceddu ML; Morelli M; Gessa GL
Ann Ist Super Sanita; 1978; 14(1):111-22. PubMed ID: 756166
[TBL] [Abstract][Full Text] [Related]
11. S 18126 ([2-[4-(2,3-dihydrobenzo[1,4]dioxin-6-yl)piperazin-1-yl methyl]indan-2-yl]), a potent, selective and competitive antagonist at dopamine D4 receptors: an in vitro and in vivo comparison with L 745,870 (3-(4-[4-chlorophenyl]piperazin-1-yl)methyl-1H-pyrrolo[2, 3b]pyridine) and raclopride.
Millan MJ; Newman-Tancredi A; Brocco M; Gobert A; Lejeune F; Audinot V; Rivet JM; Schreiber R; Dekeyne A; Spedding M; Nicolas JP; Peglion JL
J Pharmacol Exp Ther; 1998 Oct; 287(1):167-86. PubMed ID: 9765336
[TBL] [Abstract][Full Text] [Related]
12. Effects of dexfenfluramine on dopamine dependent behaviours in rats.
Thorat VM; Gaonkar RK; Bhosale KB; Balsara JJ
Indian J Physiol Pharmacol; 2005 Jan; 49(1):39-48. PubMed ID: 15881857
[TBL] [Abstract][Full Text] [Related]
13. Changes in the sensitivity to apomorphine of dopamine receptors modulating dopamine and acetylcholine release after chronic treatment with bromocriptine or haloperidol.
Cubeddu LX; Hoffmann IS; James MK; Niedzwiecki DM
J Pharmacol Exp Ther; 1983 Sep; 226(3):680-5. PubMed ID: 6887008
[TBL] [Abstract][Full Text] [Related]
14. Changes in sensitivity of release modulating dopamine autoreceptors after chronic treatment with haloperidol.
Nowak JZ; Arbilla S; Galzin AM; Langer SZ
J Pharmacol Exp Ther; 1983 Aug; 226(2):558-64. PubMed ID: 6875865
[TBL] [Abstract][Full Text] [Related]
15. Roxindole: psychopharmacological profile of a dopamine D2 autoreceptor agonist.
Bartoszyk GD; Harting J; Minck KO
J Pharmacol Exp Ther; 1996 Jan; 276(1):41-8. PubMed ID: 8558454
[TBL] [Abstract][Full Text] [Related]
16. EFFECTS OF VERAPAMIL ON DOPAMINE DEPENDENT BEHAVIOURS IN RATS.
Malekar AR; Balsara JJ; Gaonkar RK
Indian J Physiol Pharmacol; 1999 Jan; 43(1):44-52. PubMed ID: 27093735
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms for metoclopramide-mediated sensitization and haloperidol-induced catalepsy in rats.
Agovic MS; Yablonsky-Alter E; Lidsky TI; Banerjee SP
Eur J Pharmacol; 2008 Jun; 587(1-3):181-6. PubMed ID: 18457824
[TBL] [Abstract][Full Text] [Related]
18. RDS-127 (2-di-n-propylamino-4,7-dimethoxyindane): central effects of a new dopamine receptor agonist.
Arnerić SP; Long JP; Williams M; Goodale DB; Mott J; Lakoski JM; Gebhart GF
J Pharmacol Exp Ther; 1983 Jan; 224(1):161-70. PubMed ID: 6401334
[TBL] [Abstract][Full Text] [Related]
19. The effect of stimulation of pre- and postsynaptic dopamine receptors on the endogenous inhibitor of cAMP-dependent protein kinase.
Szmigielski A; Kowner A
Arch Int Pharmacodyn Ther; 1984 Dec; 272(2):205-13. PubMed ID: 6098229
[TBL] [Abstract][Full Text] [Related]
20. Neuroendocrine effects of bromperidol.
Bianchi A; Drago F; Canonico PL; Guarcello V; Carpiniello B; Scapagnini U
Acta Psychiatr Belg; 1978; 78(1):69-82. PubMed ID: 417559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
